CENTRAL NERVOUS SYSTEM DISEASE IN LANGERHANS CELL HISTIOCYTOSIS

1998 ◽  
Vol 12 (2) ◽  
pp. 287-305 ◽  
Author(s):  
Nicole G. Grois ◽  
Blaise E. Favara ◽  
Gerhard H. Mostbeck ◽  
Daniela Prayer
2010 ◽  
Vol 156 (6) ◽  
pp. 873-881.e1 ◽  
Author(s):  
Nicole Grois ◽  
Bernhard Fahrner ◽  
Robert J. Arceci ◽  
Jan-Inge Henter ◽  
Kenneth McClain ◽  
...  

2016 ◽  
Vol 65 (35) ◽  
pp. 930-933 ◽  
Author(s):  
Anita D. Sircar ◽  
Francisca Abanyie ◽  
Dean Blumberg ◽  
Peter Chin-Hong ◽  
Katrina S. Coulter ◽  
...  

2020 ◽  
Vol 60 (1) ◽  
pp. 291-309 ◽  
Author(s):  
Jesse A. Stokum ◽  
Volodymyr Gerzanich ◽  
Kevin N. Sheth ◽  
W. Taylor Kimberly ◽  
J. Marc Simard

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.


2021 ◽  
Vol 432 ◽  
pp. 213751
Author(s):  
Ke Chen ◽  
Si Sun ◽  
Junying Wang ◽  
Xiao-Dong Zhang

Sign in / Sign up

Export Citation Format

Share Document